Medicine Henry Quentir Medicine Henry Quentir

Chugai, QSimulate and Mitsui Test QIDO Quantum-Classical Chemistry on Drug-Substance Synthesis Reactions in Japan's JHPC-quantum Program, 12 November 2026

What Chugai, QSimulate and Mitsui announced in Tokyo on 12 November 2026

Quentir Medicine Monitor

Evidence-based insights for quantum medicine.

Chugai Pharmaceutical will test whether a quantum computer can sharpen one hard question in its chemistry labs: which reaction route makes a complex medicine cleanly, and which side reactions compete with it. The work is part of a quantum-classical hybrid project with QSimulate and Mitsui & Co., announced in Tokyo on 12 November 2026, and it targets drug-substance synthesis, the chemistry that produces the active ingredient of a medicine.

The announcement has two parts. The three companies will extend QIDO, a computational chemistry platform sold by Mitsui and QSimulate, with functions built around needs that came out of Chugai's own evaluation of the software. Separately, a research theme with Chugai as lead proposer and QSimulate as co-proposer has been selected for the JHPC-quantum Test User Program, a Japanese government-funded platform that links quantum computers with supercomputers. Mitsui joins that theme as a cooperating party. The Japanese press release on PR TIMES and a shorter English notice from QSimulate carry the details. The announcement reports no calculation results.

QIDO stands for Quantum-Integrated Discovery Orchestrator. Mitsui, QSimulate and the quantum computing company Quantinuum launched it in August 2025, and it incorporates Quantinuum's InQuanto quantum chemistry software. According to the QIDO product page, the classical side of the platform already identifies transition states automatically once a chemist specifies reactants and products, and computes more precise energies with post-Hartree-Fock methods on an active space of electrons chosen with the AVAS method. The quantum side is where InQuanto comes in.

The new functions listed in the release fall into three groups. The first deepens reaction-mechanism analysis and reaction-path search for the complex molecules and reactions that pharmaceutical research handles. The second extends workflows that generate and evaluate candidate structures for reactants, products, intermediates and transition states. The third improves the interface through which a chemist sets and checks calculation conditions. The companies say these functions will enter the QIDO product roadmap and be offered to other pharmaceutical and chemical companies as general product features, so requirements that came from Chugai's laboratories will shape software that other companies can buy.

Read More